导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 23.68% | 185/4773 |
| 近一周 | -1.99% | 1030/5462 |
| 近一月 | 1.03% | 456/5421 |
| 近一季 | 1.79% | 511/5209 |
| 近半年 | -2.52% | 1930/4920 |
| 近一年 | 22.86% | 334/4366 |
| 近两年 | 33.19% | 2153/2954 |
| 近三年 | 21.37% | 1421/2253 |
| 成立以来 | 186.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
18.10% 33/4961 |
-11.51% 4300/5312 |
- - |
- - |
| 2025 | -5.17% 3368/4813 |
-9.64% 3436/3635 |
-2.04% 3297/4076 |
7.40% 3452/4524 |
-0.25% 2439/4813 |
| 2024 | 1.22% 2022/3463 |
7.53% 240/2808 |
-0.83% 850/3014 |
4.75% 2890/3129 |
-9.38% 2924/3463 |
| 2023 | 10.09% 103/2656 |
3.20% 1241/2280 |
-6.04% 1580/2385 |
9.46% 9/2515 |
3.72% 49/2655 |
| 2022 | 16.21% 3/2207 |
21.42% 3/1919 |
8.96% 312/2016 |
4.04% 7/2113 |
-15.57% 2079/2208 |
| 2021 | 48.00% 9/1822 |
4.15% 159/1255 |
22.07% 127/1330 |
36.49% 8/1466 |
-14.71% 1632/1822 |
| 2020 | - - |
- - |
1.77% 986/1067 |
12.33% 395/1164 |
17.89% 110/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证煤炭ETF联接C VS. 长安沪深300非周期A(740101) |